Certara Key Executives
This section highlights Certara's key executives, including their titles and compensation details.
Find Contacts at Certara
(Showing 0 of )
Certara Earnings
This section highlights Certara's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Date:
May 05, 2025
Time:
After Market
Est. EPS:
$0.13
Status:
Unconfirmed
Last Earnings Results
Date:
February 26, 2025
EPS:
$0.15
Est. EPS:
$0.13
Revenue:
$100.36M
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|---|---|---|---|---|
| Read Transcript | Q4 | 2024 | 2025-02-26 | $0.13 | $0.15 |
| Read Transcript | Q3 | 2024 | 2024-11-06 | $0.11 | $0.13 |
| Read Transcript | Q2 | 2024 | 2024-08-06 | $0.11 | $0.07 |
| Read Transcript | Q1 | 2024 | 2024-05-07 | $0.10 | $0.10 |
| Read Transcript | Q4 | 2023 | 2024-02-29 | $0.11 | $0.09 |
| Read Transcript | Q3 | 2023 | 2023-11-08 | $0.11 | $0.11 |
| Read Transcript | Q2 | 2023 | 2023-08-09 | $0.13 | $0.12 |
| Read Transcript | Q1 | 2023 | 2023-05-08 | $0.12 | $0.12 |
Certara, Inc. provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access. It offers medicines to patients using biosimulation software, technology, and services to transform drug discovery and development. The company also provides related technology-enabled services to guide its customers' new drugs through the regulatory submission process and into the market. Its technology-enabled services include mechanistic biosimulation, empirical biosimulation, drug development and regulatory strategy, clinical pharmacology, model-based meta-analysis, regulatory writing and medical communications, regulatory operations, and market access. Further, company offers software, comprising mechanistic biosimulation platform, empirical PK/PD biosimulation platform, data standardization and compliance software, scientific informatics platform, clinical outcomes databases for biosimulation, authoring and management of regulatory submissions platform, and market access communication platform. The company serves biopharmaceutical companies, and academic and government institutions. It has operations in the United States, Canada, Spain, Luxembourg, Portugal, the United Kingdom, Germany, France, the Netherlands, Denmark, Switzerland, Italy, Poland, Japan, the Philippines, India, Australia, and China. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.
Healthcare
Medical - Healthcare Information Services
$14.17
Stock Price
$2.29B
Market Cap
1.55K
Employees
Princeton, NJ
Location
Financial Statements
Access annual & quarterly financial statements for Certara, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $385.15M | $354.34M | $335.64M | $286.10M | $243.53M |
| Cost of Revenue | $154.52M | $141.02M | $132.58M | $111.62M | $100.77M |
| Gross Profit | $230.63M | $213.31M | $203.07M | $174.49M | $142.76M |
| Gross Profit Ratio | 59.88% | 60.20% | 60.50% | 60.99% | 58.62% |
| Research and Development Expenses | $37.10M | $34.17M | $28.20M | $20.38M | $19.64M |
| General and Administrative Expenses | $94.22M | $95.39M | $71.77M | $79.54M | $88.48M |
| Selling and Marketing Expenses | $47.44M | $32.02M | $27.41M | $20.14M | $19.20M |
| Selling General and Administrative Expenses | $141.66M | $127.41M | $99.18M | $99.68M | $107.68M |
| Other Expenses | $53.59M | $92.51M | $43.16M | $40.85M | $39.86M |
| Operating Expenses | $232.36M | $254.09M | $170.55M | $160.91M | $167.19M |
| Cost and Expenses | $386.88M | $395.11M | $303.12M | $272.52M | $267.95M |
| Interest Income | $- | $- | $17.77M | $16.84M | $25.30M |
| Interest Expense | $21.52M | $22.92M | $17.77M | $16.84M | $25.30M |
| Depreciation and Amortization | $1.99M | $56.07M | $52.47M | $45.12M | $42.75M |
| EBITDA | $-36.71M | $23.84M | $89.00M | $58.58M | $17.87M |
| EBITDA Ratio | -9.53% | 6.73% | 26.52% | 20.47% | 7.34% |
| Operating Income | $-1.73M | $-40.77M | $32.52M | $13.58M | $-24.89M |
| Operating Income Ratio | -0.45% | -11.51% | 9.69% | 4.75% | -10.22% |
| Total Other Income Expenses Net | $-15.45M | $-14.37M | $-13.77M | $-16.95M | $-25.76M |
| Income Before Tax | $-17.18M | $-55.14M | $18.75M | $-3.38M | $-50.18M |
| Income Before Tax Ratio | -4.46% | -15.56% | 5.59% | -1.18% | -20.61% |
| Income Tax Expense | $-5.13M | $214.00K | $4.02M | $9.89M | $-784.00K |
| Net Income | $-12.05M | $-55.36M | $14.73M | $-13.27M | $-49.40M |
| Net Income Ratio | -3.13% | -15.62% | 4.39% | -4.64% | -20.28% |
| EPS | $-0.08 | $-0.35 | $0.09 | $-0.09 | $-0.32 |
| EPS Diluted | $-0.08 | $-0.35 | $0.09 | $-0.09 | $-0.32 |
| Weighted Average Shares Outstanding | 160.39M | 158.94M | 156.88M | 149.84M | 152.98M |
| Weighted Average Shares Outstanding Diluted | 160.39M | 158.94M | 159.35M | 149.84M | 152.98M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $100.36M | $94.82M | $93.31M | $96.65M | $88.01M | $85.58M | $90.45M | $90.30M | $86.63M | $84.70M | $82.76M | $81.55M | $75.35M | $73.94M | $70.10M | $66.72M | $64.64M | $60.32M | $61.12M | $57.45M |
| Cost of Revenue | $38.26M | $37.19M | $53.00M | $52.28M | $46.18M | $35.88M | $36.22M | $34.86M | $31.78M | $32.81M | $35.19M | $32.79M | $29.29M | $28.77M | $27.54M | $26.02M | $34.91M | $23.03M | $20.65M | $22.18M |
| Gross Profit | $62.10M | $57.63M | $40.31M | $44.37M | $41.83M | $49.70M | $54.23M | $55.45M | $54.85M | $51.89M | $47.57M | $48.76M | $46.06M | $45.17M | $42.55M | $40.70M | $29.74M | $37.29M | $40.48M | $35.27M |
| Gross Profit Ratio | 61.87% | 60.78% | 43.20% | 45.91% | 47.53% | 58.08% | 59.95% | 61.40% | 63.31% | 61.26% | 57.47% | 59.79% | 61.13% | 61.09% | 60.71% | 61.01% | 46.00% | 61.82% | 66.22% | 61.39% |
| Research and Development Expenses | $7.77M | $8.27M | $9.07M | $11.99M | $8.02M | $8.98M | $7.89M | $9.29M | $6.60M | $6.32M | $7.74M | $7.55M | $6.52M | $4.53M | $4.63M | $4.71M | $10.51M | $3.29M | $2.97M | $2.88M |
| General and Administrative Expenses | $21.14M | $22.03M | $28.07M | $22.98M | $33.61M | $27.76M | $14.24M | $19.77M | $18.33M | $17.33M | $17.78M | $18.34M | $18.74M | $26.20M | $18.03M | $16.56M | $52.36M | $13.40M | $11.18M | $11.54M |
| Selling and Marketing Expenses | $13.20M | $11.35M | $12.21M | $10.69M | $8.67M | $7.24M | $8.11M | $8.00M | $7.80M | $6.38M | $7.12M | $6.11M | $6.72M | $5.08M | $4.59M | $3.75M | $10.43M | $3.11M | $2.73M | $2.94M |
| Selling General and Administrative Expenses | $34.34M | $33.38M | $34.27M | $31.90M | $37.90M | $35.00M | $22.36M | $27.77M | $26.13M | $23.70M | $24.90M | $24.45M | $25.46M | $31.28M | $22.62M | $20.31M | $62.79M | $16.51M | $13.91M | $14.48M |
| Other Expenses | $13.98M | $13.39M | $2.35M | $1.60M | $1.95M | $5.08M | $1.01M | $10.95M | $10.74M | $11.01M | $10.78M | $10.63M | $-311.00K | $657.00K | $-346.00K | $-117.00K | $-921.00K | $11.00K | $-80.00K | $525.00K |
| Operating Expenses | $56.09M | $55.04M | $43.33M | $43.90M | $45.92M | $55.50M | $41.19M | $48.01M | $43.47M | $41.03M | $43.42M | $42.63M | $42.62M | $45.94M | $37.28M | $35.08M | $83.26M | $29.79M | $26.87M | $27.27M |
| Cost and Expenses | $94.36M | $92.23M | $96.33M | $96.18M | $92.10M | $91.38M | $77.41M | $82.86M | $75.25M | $73.84M | $78.61M | $75.42M | $71.90M | $74.70M | $64.82M | $61.09M | $118.16M | $52.82M | $47.52M | $49.45M |
| Interest Income | $- | $- | $- | $- | $- | $- | $5.67M | $5.47M | $- | $5.22M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Interest Expense | $5.00M | $5.19M | $5.58M | $5.75M | $5.87M | $5.90M | $5.67M | $5.47M | $5.45M | $5.22M | $3.88M | $3.23M | $3.29M | $3.29M | $6.33M | $3.93M | $5.49M | $5.93M | $7.02M | $6.86M |
| Depreciation and Amortization | $18.22M | $439.00K | $16.60M | $16.43M | $14.83M | $14.18M | $13.53M | $13.52M | $13.14M | $13.26M | $13.13M | $12.93M | $12.99M | $10.74M | $10.68M | $10.70M | $11.11M | $10.57M | $10.59M | $10.48M |
| EBITDA | $25.40M | $-6.41M | $9.91M | $16.91M | $8.32M | $-33.53M | $27.58M | $21.47M | $26.75M | $26.98M | $19.80M | $19.91M | $27.71M | $10.64M | $15.61M | $16.21M | $-43.33M | $18.08M | $24.11M | $19.01M |
| EBITDA Ratio | 25.31% | -6.76% | 10.62% | 17.49% | 9.45% | -39.18% | 30.50% | 23.77% | 30.88% | 31.85% | 23.93% | 24.41% | 36.77% | 14.39% | 22.26% | 24.30% | -67.03% | 29.97% | 39.45% | 33.09% |
| Operating Income | $6.00M | $2.59M | $-3.02M | $478.00K | $-4.09M | $-52.78M | $13.04M | $7.44M | $11.38M | $10.86M | $6.67M | $6.13M | $3.44M | $-761.00K | $5.27M | $5.62M | $-53.52M | $7.50M | $13.61M | $8.00M |
| Operating Income Ratio | 5.98% | 2.74% | -3.24% | 0.49% | -4.64% | -61.68% | 14.42% | 8.24% | 13.14% | 12.82% | 8.06% | 7.52% | 4.57% | -1.03% | 7.52% | 8.43% | -82.80% | 12.43% | 22.26% | 13.93% |
| Total Other Income Expenses Net | $-3.82M | $-4.25M | $-3.23M | $-5.91M | $-3.92M | $-825.00K | $-4.66M | $-4.97M | $-7.66M | $-2.37M | $-1.36M | $-2.39M | $-3.60M | $-2.63M | $-6.68M | $-4.04M | $-6.41M | $-5.92M | $-7.10M | $-6.33M |
| Income Before Tax | $2.18M | $-1.66M | $-12.27M | $-5.43M | $-12.38M | $-53.61M | $8.38M | $2.47M | $3.73M | $8.49M | $2.79M | $3.75M | $-157.00K | $-3.39M | $-1.40M | $1.58M | $-59.93M | $1.58M | $6.50M | $1.67M |
| Income Before Tax Ratio | 2.17% | -1.75% | -13.15% | -5.62% | -14.07% | -62.64% | 9.27% | 2.73% | 4.30% | 10.03% | 3.37% | 4.59% | -0.21% | -4.59% | -2.00% | 2.37% | -92.71% | 2.61% | 10.64% | 2.90% |
| Income Tax Expense | $-4.40M | $-290.00K | $305.00K | $-751.00K | $72.00K | $-4.64M | $3.67M | $1.11M | $-5.45M | $4.56M | $3.38M | $1.54M | $9.54M | $-1.63M | $1.45M | $527.00K | $-5.48M | $350.00K | $3.73M | $621.00K |
| Net Income | $6.58M | $-1.37M | $-12.57M | $-4.68M | $-12.46M | $-48.97M | $4.71M | $1.36M | $9.17M | $3.94M | $-589.00K | $2.21M | $-9.70M | $-1.76M | $-2.86M | $1.05M | $-54.45M | $1.23M | $2.78M | $1.05M |
| Net Income Ratio | 6.55% | -1.45% | -13.48% | -4.85% | -14.15% | -57.22% | 5.20% | 1.50% | 10.59% | 4.65% | -0.71% | 2.71% | -12.87% | -2.38% | -4.08% | 1.58% | -84.23% | 2.03% | 4.54% | 1.82% |
| EPS | $0.04 | $-0.01 | $-0.08 | $-0.03 | $-0.08 | $-0.31 | $0.03 | $0.01 | $0.06 | $0.03 | $0.00 | $0.01 | $-0.06 | $-0.01 | $-0.02 | $0.01 | $-0.40 | $0.01 | $0.02 | $0.01 |
| EPS Diluted | $0.04 | $-0.01 | $-0.08 | $-0.03 | $-0.08 | $-0.31 | $0.03 | $0.01 | $0.06 | $0.02 | $0.00 | $0.01 | $-0.06 | $-0.01 | $-0.02 | $0.01 | $-0.40 | $0.01 | $0.02 | $0.01 |
| Weighted Average Shares Outstanding | 160.39M | 160.64M | 160.51M | 159.52M | 159.43M | 159.17M | 158.96M | 158.18M | 157.93M | 157.14M | 156.48M | 155.94M | 155.62M | 149.02M | 142.86M | 147.16M | 135.37M | 152.68M | 152.98M | 152.98M |
| Weighted Average Shares Outstanding Diluted | 160.39M | 160.64M | 160.51M | 159.52M | 159.43M | 159.17M | 159.91M | 159.73M | 159.24M | 159.59M | 156.48M | 159.16M | 155.62M | 149.02M | 147.49M | 152.08M | 135.75M | 152.68M | 152.98M | 152.98M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $179.18M | $234.95M | $236.59M | $185.80M | $271.38M |
| Short Term Investments | $- | $- | $4.64M | $57.00K | $- |
| Cash and Short Term Investments | $179.18M | $234.95M | $236.59M | $185.80M | $271.38M |
| Net Receivables | $102.19M | $93.26M | $88.81M | $78.31M | $54.09M |
| Inventory | $- | $- | $3.10M | $827.00K | $1.91M |
| Other Current Assets | $29.48M | $11.99M | $16.86M | $10.62M | $21.11M |
| Total Current Assets | $310.85M | $340.20M | $342.25M | $274.73M | $346.58M |
| Property Plant Equipment Net | $16.01M | $12.27M | $16.83M | $15.57M | $3.87M |
| Goodwill | $757.04M | $716.33M | $717.74M | $703.37M | $518.59M |
| Intangible Assets | $485.21M | $487.04M | $486.78M | $511.82M | $396.44M |
| Goodwill and Intangible Assets | $1.24B | $1.20B | $1.20B | $1.22B | $915.04M |
| Long Term Investments | $- | $1.15M | $3.74M | $- | $- |
| Tax Assets | $3.96M | $4.24M | $3.70M | $4.07M | $2.74M |
| Other Non-Current Assets | $2.03M | $1.90M | $1.88M | $2.17M | $1.16M |
| Total Non-Current Assets | $1.26B | $1.22B | $1.23B | $1.24B | $922.82M |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $1.58B | $1.56B | $1.57B | $1.51B | $1.27B |
| Account Payables | $3.50M | $5.17M | $7.53M | $7.46M | $6.39M |
| Short Term Debt | $8.31M | $7.39M | $8.01M | $8.35M | $5.23M |
| Tax Payables | $430.00K | $1.01M | $2.22M | $1.40M | $912.00K |
| Deferred Revenue | $77.83M | $60.68M | $52.21M | $45.50M | $30.66M |
| Other Current Liabilities | $56.02M | $55.77M | $33.18M | $29.52M | $32.15M |
| Total Current Liabilities | $146.09M | $130.02M | $103.16M | $92.22M | $75.34M |
| Long Term Debt | $22.33M | $295.17M | $300.12M | $300.03M | $294.42M |
| Deferred Revenue Non-Current | $1.05M | $1.07M | $2.81M | $1.53M | $545.00K |
| Deferred Tax Liabilities Non-Current | $40.42M | $50.83M | $65.05M | $76.10M | $75.89M |
| Other Non-Current Liabilities | $306.56M | $39.21M | $22.12M | $- | $1.07M |
| Total Non-Current Liabilities | $370.36M | $386.28M | $390.10M | $377.66M | $371.92M |
| Other Liabilities | $- | $1 | $- | $- | $- |
| Total Liabilities | $516.45M | $516.30M | $493.26M | $469.88M | $447.27M |
| Preferred Stock | $- | $- | $- | $- | $- |
| Common Stock | $1.62M | $1.60M | $1.60M | $1.60M | $1.53M |
| Retained Earnings | $-128.28M | $-116.23M | $-60.87M | $-75.60M | $-62.34M |
| Accumulated Other Comprehensive Income Loss | $-13.42M | $-7.59M | $-8.23M | $-3.93M | $-1.59M |
| Other Total Stockholders Equity | $1.20B | $1.17B | $1.15B | $1.12B | $884.53M |
| Total Stockholders Equity | $1.06B | $1.05B | $1.08B | $1.04B | $822.13M |
| Total Equity | $1.06B | $1.05B | $1.08B | $1.04B | $822.13M |
| Total Liabilities and Stockholders Equity | $1.58B | $1.56B | $1.57B | $1.51B | $1.27B |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $1.58B | $1.56B | $1.57B | $1.51B | $1.27B |
| Total Investments | $- | $1.15M | $3.74M | $57.00K | $- |
| Total Debt | $14.17M | $302.57M | $308.11M | $303.02M | $299.37M |
| Net Debt | $-165.02M | $67.62M | $71.52M | $117.22M | $27.99M |
Balance Sheet Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $179.18M | $233.02M | $224.60M | $224.78M | $234.95M | $272.31M | $245.19M | $244.13M | $236.59M | $210.51M | $194.75M | $184.31M | $185.80M | $416.85M | $267.76M | $272.99M | $271.38M | $29.94M | $55.67M | $-29.26M |
| Short Term Investments | $- | $- | $5.03M | $5.03M | $4.47M | $5.88M | $5.67M | $4.26M | $- | $3.43M | $680.00K | $181.00K | $57.00K | $- | $- | $- | $- | $- | $- | $58.51M |
| Cash and Short Term Investments | $179.18M | $233.02M | $224.60M | $224.78M | $234.95M | $272.31M | $245.19M | $244.13M | $236.59M | $210.51M | $194.75M | $184.31M | $185.80M | $416.85M | $267.76M | $272.99M | $271.38M | $29.94M | $55.67M | $29.26M |
| Net Receivables | $102.19M | $95.96M | $98.05M | $89.15M | $93.26M | $83.20M | $89.10M | $82.40M | $88.81M | $80.55M | $78.25M | $80.37M | $78.31M | $62.86M | $56.59M | $54.40M | $54.09M | $48.83M | $51.69M | $- |
| Inventory | $- | $- | $-5.03M | $-5.03M | $-4.47M | $13.44M | $3.02M | $3.10M | $- | $13.02M | $12.20M | $9.51M | $-8.75M | $1.11M | $1.84M | $733.00K | $1.91M | $1.81M | $- | $- |
| Other Current Assets | $29.48M | $21.63M | $14.43M | $14.53M | $11.99M | $14.27M | $18.75M | $17.45M | $16.86M | $14.04M | $13.02M | $10.51M | $10.62M | $25.14M | $20.46M | $20.17M | $21.11M | $14.03M | $14.23M | $- |
| Total Current Assets | $310.85M | $350.61M | $337.08M | $328.46M | $340.20M | $369.78M | $353.04M | $348.25M | $342.25M | $305.09M | $286.02M | $275.19M | $274.73M | $504.85M | $344.81M | $347.56M | $346.58M | $92.80M | $121.59M | $29.26M |
| Property Plant Equipment Net | $16.01M | $14.62M | $16.93M | $17.14M | $12.27M | $11.85M | $14.53M | $15.72M | $16.83M | $14.09M | $15.05M | $16.56M | $15.57M | $3.00M | $3.07M | $3.50M | $3.87M | $4.36M | $4.78M | $- |
| Goodwill | $757.04M | $718.48M | $715.52M | $715.62M | $716.33M | $673.16M | $721.85M | $718.84M | $717.74M | $696.92M | $700.80M | $704.79M | $703.37M | $522.81M | $524.26M | $519.23M | $518.59M | $515.59M | $513.38M | $- |
| Intangible Assets | $485.21M | $453.23M | $463.15M | $473.69M | $487.04M | $463.11M | $473.81M | $476.55M | $486.78M | $481.54M | $493.05M | $504.31M | $511.82M | $378.99M | $387.94M | $388.23M | $396.44M | $404.25M | $411.41M | $- |
| Goodwill and Intangible Assets | $1.24B | $1.17B | $1.18B | $1.19B | $1.20B | $1.14B | $1.20B | $1.20B | $1.20B | $1.18B | $1.19B | $1.21B | $1.22B | $901.80M | $912.21M | $907.45M | $915.04M | $919.84M | $924.79M | $- |
| Long Term Investments | $- | $- | $577.00K | $1.34M | $1.15M | $3.46M | $3.52M | $1.83M | $- | $4.96M | $- | $- | $- | $1.15M | $1.17M | $- | $- | $- | $- | $- |
| Tax Assets | $3.96M | $4.24M | $4.24M | $4.24M | $4.24M | $3.70M | $3.70M | $3.70M | $3.70M | $4.16M | $4.15M | $4.09M | $4.07M | $2.92M | $2.94M | $2.92M | $2.74M | $815.00K | $- | $- |
| Other Non-Current Assets | $2.03M | $2.05M | $2.11M | $1.90M | $1.90M | $1.75M | $1.76M | $1.85M | $5.62M | $1.94M | $2.68M | $2.10M | $2.17M | $1.07M | $1.15M | $1.18M | $1.16M | $2.57M | $5.22M | $-29.26M |
| Total Non-Current Assets | $1.26B | $1.19B | $1.20B | $1.21B | $1.22B | $1.16B | $1.22B | $1.22B | $1.23B | $1.20B | $1.22B | $1.23B | $1.24B | $909.94M | $920.53M | $915.06M | $922.82M | $927.58M | $934.79M | $-29.26M |
| Other Assets | $- | $- | $- | $1 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $1.58B | $1.54B | $1.54B | $1.54B | $1.56B | $1.53B | $1.57B | $1.57B | $1.57B | $1.51B | $1.50B | $1.51B | $1.51B | $1.41B | $1.27B | $1.26B | $1.27B | $1.02B | $1.06B | $- |
| Account Payables | $3.50M | $2.49M | $4.80M | $3.73M | $5.17M | $5.26M | $3.79M | $4.33M | $7.53M | $3.00M | $5.24M | $6.25M | $7.46M | $11.26M | $5.55M | $6.59M | $6.39M | $5.44M | $4.03M | $- |
| Short Term Debt | $8.31M | $3.00M | $31.69M | $11.68M | $7.39M | $7.47M | $7.67M | $12.64M | $8.01M | $6.54M | $7.79M | $8.16M | $8.35M | $3.60M | $3.59M | $5.24M | $5.23M | $6.12M | $5.70M | $- |
| Tax Payables | $430.00K | $1.70M | $4.23M | $1.32M | $1.01M | $7.67M | $6.54M | $3.70M | $2.22M | $1.84M | $2.90M | $1.08M | $1.40M | $- | $- | $- | $912.00K | $- | $- | $- |
| Deferred Revenue | $77.83M | $59.34M | $60.99M | $56.80M | $60.68M | $47.98M | $52.79M | $51.65M | $52.21M | $40.43M | $46.12M | $48.17M | $45.50M | $27.99M | $29.12M | $29.80M | $30.66M | $24.90M | $- | $- |
| Other Current Liabilities | $56.02M | $56.17M | $56.10M | $27.09M | $55.77M | $37.06M | $32.12M | $21.50M | $33.18M | $24.71M | $19.49M | $17.95M | $29.52M | $26.79M | $20.99M | $21.74M | $32.15M | $48.79M | $47.25M | $- |
| Total Current Liabilities | $146.09M | $122.70M | $129.12M | $100.63M | $130.02M | $105.43M | $102.90M | $93.82M | $103.16M | $76.53M | $81.55M | $81.62M | $92.22M | $69.63M | $59.25M | $63.37M | $75.34M | $60.34M | $56.98M | $- |
| Long Term Debt | $22.33M | $303.47M | $304.83M | $299.40M | $295.17M | $295.89M | $297.39M | $298.79M | $300.12M | $298.94M | $299.16M | $300.66M | $300.03M | $292.28M | $292.80M | $293.94M | $294.42M | $378.13M | $419.09M | $- |
| Deferred Revenue Non-Current | $1.05M | $- | $1.19M | $1.44M | $1.07M | $1.24M | $2.06M | $2.78M | $2.81M | $1.88M | $2.28M | $1.08M | $1.53M | $1.23M | $1.16M | $853.00K | $545.00K | $885.00K | $- | $- |
| Deferred Tax Liabilities Non-Current | $40.42M | $- | $37.52M | $46.31M | $50.83M | $46.40M | $54.68M | $62.92M | $67.35M | $75.52M | $70.38M | $75.27M | $76.10M | $79.63M | $76.93M | $76.08M | $75.89M | $83.48M | $- | $- |
| Other Non-Current Liabilities | $306.56M | $63.65M | $23.54M | $40.24M | $39.21M | $26.11M | $18.03M | $23.40M | $19.81M | $1.42M | $- | $- | $- | $686.00K | $690.00K | $1.11M | $1.07M | $84.37M | $88.12M | $- |
| Total Non-Current Liabilities | $370.36M | $367.12M | $367.09M | $387.39M | $386.28M | $369.64M | $372.15M | $387.89M | $390.10M | $377.76M | $371.82M | $377.00M | $377.66M | $373.83M | $371.58M | $371.99M | $371.92M | $462.50M | $507.21M | $- |
| Other Liabilities | $- | $- | $1 | $1 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $516.45M | $489.82M | $496.21M | $488.02M | $516.30M | $475.07M | $475.05M | $481.70M | $493.26M | $454.30M | $453.37M | $458.62M | $469.88M | $443.47M | $430.82M | $435.36M | $447.27M | $522.84M | $564.19M | $- |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock | $1.62M | $1.62M | $1.62M | $1.61M | $1.60M | $1.60M | $1.60M | $1.60M | $1.60M | $1.60M | $1.60M | $1.60M | $1.60M | $1.57M | $1.53M | $1.53M | $1.53M | $1.32M | $- | $- |
| Retained Earnings | $-128.28M | $-134.86M | $-133.49M | $-120.91M | $-116.23M | $-103.77M | $-54.81M | $-59.52M | $-60.87M | $-70.05M | $-73.98M | $-73.39M | $-75.60M | $-65.91M | $-64.14M | $-61.29M | $-62.34M | $-7.89M | $-9.12M | $- |
| Accumulated Other Comprehensive Income Loss | $-13.42M | $-5.01M | $-8.33M | $-7.04M | $-7.59M | $-7.71M | $-3.17M | $-7.32M | $-8.23M | $-17.93M | $-13.72M | $-7.05M | $-3.93M | $-2.93M | $-85.00K | $-2.65M | $-1.59M | $-6.51M | $-10.23M | $492.05M |
| Other Total Stockholders Equity | $1.20B | $1.19B | $1.18B | $1.18B | $1.17B | $1.16B | $1.15B | $1.15B | $1.15B | $1.14B | $1.13B | $1.13B | $1.12B | $1.04B | $897.21M | $889.68M | $884.53M | $511.94M | $511.54M | $- |
| Total Stockholders Equity | $1.06B | $1.05B | $1.04B | $1.05B | $1.05B | $1.05B | $1.10B | $1.09B | $1.08B | $1.05B | $1.05B | $1.05B | $1.04B | $971.32M | $834.51M | $827.27M | $822.13M | $497.54M | $492.19M | $492.05M |
| Total Equity | $1.06B | $1.05B | $1.04B | $1.05B | $1.05B | $1.05B | $1.10B | $1.09B | $1.08B | $1.05B | $1.05B | $1.05B | $1.04B | $971.32M | $834.51M | $827.27M | $822.13M | $497.54M | $492.19M | $492.05M |
| Total Liabilities and Stockholders Equity | $1.58B | $1.54B | $1.54B | $1.54B | $1.56B | $1.53B | $1.57B | $1.57B | $1.57B | $1.51B | $1.50B | $1.51B | $1.51B | $1.41B | $1.27B | $1.26B | $1.27B | $1.02B | $1.06B | $492.05M |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $1.58B | $1.54B | $1.54B | $1.54B | $1.56B | $1.53B | $1.57B | $1.57B | $1.57B | $1.51B | $1.50B | $1.51B | $1.51B | $1.41B | $1.27B | $1.26B | $1.27B | $1.02B | $1.06B | $492.05M |
| Total Investments | $- | $- | $577.00K | $1.34M | $1.15M | $3.46M | $3.52M | $1.83M | $- | $4.96M | $680.00K | $181.00K | $57.00K | $1.15M | $1.17M | $- | $- | $- | $- | $58.51M |
| Total Debt | $14.17M | $306.47M | $312.55M | $306.75M | $298.19M | $303.36M | $300.41M | $306.62M | $308.13M | $305.38M | $306.96M | $308.82M | $303.02M | $295.59M | $296.10M | $298.89M | $299.37M | $379.84M | $424.52M | $- |
| Net Debt | $-165.02M | $73.45M | $87.95M | $81.98M | $63.24M | $31.05M | $55.22M | $62.48M | $71.55M | $94.87M | $112.20M | $124.50M | $117.22M | $-121.26M | $28.34M | $25.91M | $27.99M | $349.90M | $368.85M | $29.26M |
Annual Cash Flow
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $-12.05M | $-55.36M | $14.73M | $-13.27M | $-49.40M |
| Depreciation and Amortization | $68.03M | $56.07M | $52.47M | $45.12M | $42.75M |
| Deferred Income Tax | $-12.70M | $-16.52M | $-11.51M | $-1.18M | $-7.83M |
| Stock Based Compensation | $34.77M | $28.30M | $30.34M | $29.48M | $64.51M |
| Change in Working Capital | $- | $-4.72M | $3.73M | $-2.92M | $-6.71M |
| Accounts Receivables | $-16.23M | $152.00K | $-15.01M | $-10.07M | $-3.93M |
| Inventory | $- | $- | $- | $-1.13M | $-8.26M |
| Accounts Payables | $-4.76M | $-5.61M | $5.29M | $1.13M | $2.38M |
| Other Working Capital | $- | $739.00K | $13.45M | $7.15M | $3.09M |
| Other Non Cash Items | $2.40M | $74.98M | $2.78M | $3.16M | $1.49M |
| Net Cash Provided by Operating Activities | $80.47M | $82.75M | $92.54M | $60.39M | $44.81M |
| Investments in Property Plant and Equipment | $-1.62M | $-1.78M | $-12.53M | $-8.90M | $-7.94M |
| Acquisitions Net | $-91.33M | $-64.23M | $-15.31M | $-261.02M | $-675.00K |
| Purchases of Investments | $- | $- | $- | $- | $- |
| Sales Maturities of Investments | $- | $- | $- | $- | $- |
| Other Investing Activities | $-19.42M | $-13.55M | $-11.10M | $-7.76M | $-7.07M |
| Net Cash Used for Investing Activities | $-112.37M | $-79.55M | $-27.84M | $-269.92M | $-8.61M |
| Debt Repayment | $4.05M | $-3.04M | $-3.31M | $-3.88M | $-104.36M |
| Common Stock Issued | $- | $- | $- | $133.35M | $316.55M |
| Common Stock Repurchased | $- | $-6.40M | $-2.96M | $- | $-1.08M |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $-25.06M | $-6.40M | $-4.05M | $-6.08M | $-2.90M |
| Net Cash Used Provided by Financing Activities | $-21.01M | $-9.45M | $-7.36M | $123.39M | $208.21M |
| Effect of Forex Changes on Cash | $-2.86M | $1.50M | $-4.28M | $-524.00K | $-883.00K |
| Net Change in Cash | $-55.77M | $-4.74M | $53.06M | $-86.67M | $243.53M |
| Cash at End of Period | $179.18M | $234.95M | $239.69M | $186.62M | $273.29M |
| Cash at Beginning of Period | $234.95M | $239.69M | $186.62M | $273.29M | $29.76M |
| Operating Cash Flow | $80.47M | $82.75M | $92.54M | $60.39M | $44.81M |
| Capital Expenditure | $-1.62M | $-15.32M | $-12.53M | $-8.90M | $-7.94M |
| Free Cash Flow | $78.84M | $67.43M | $80.01M | $51.49M | $36.87M |
Cash Flow Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $6.58M | $-1.37M | $-12.57M | $-4.68M | $-12.46M | $-48.97M | $4.71M | $1.36M | $9.17M | $3.94M | $-589.00K | $2.21M | $-9.70M | $-1.76M | $-2.86M | $1.05M | $-54.45M | $1.23M | $2.78M | $1.05M |
| Depreciation and Amortization | $18.22M | $16.79M | $16.60M | $16.43M | $14.83M | $14.18M | $13.53M | $13.52M | $13.14M | $13.26M | $13.13M | $12.93M | $12.99M | $10.74M | $10.68M | $10.70M | $11.11M | $10.57M | $10.59M | $10.48M |
| Deferred Income Tax | $-69.00K | $789.00K | $-8.59M | $-4.83M | $2.01M | $-8.29M | $-8.71M | $-1.52M | $-8.30M | $2.40M | $-4.89M | $-715.00K | $-2.98M | $3.77M | $-1.98M | $12.00K | $-9.09M | $-608.00K | $787.00K | $1.08M |
| Stock Based Compensation | $7.73M | $8.19M | $9.78M | $9.07M | $7.50M | $8.64M | $3.61M | $8.54M | $6.53M | $6.80M | $9.50M | $7.51M | $8.64M | $8.16M | $7.53M | $5.15M | $62.22M | $1.18M | $567.00K | $538.00K |
| Change in Working Capital | $13.86M | $14.55M | $485.00K | $-15.04M | $-2.41M | $7.90M | $3.22M | $-13.42M | $13.84M | $-3.09M | $5.54M | $-12.56M | $11.96M | $-789.00K | $-1.73M | $-12.36M | $2.58M | $2.70M | $-7.30M | $-4.69M |
| Accounts Receivables | $-5.25M | $-4.37M | $-10.24M | $3.63M | $-6.29M | $6.71M | $-919.00K | $647.00K | $-7.11M | $-2.19M | $-2.46M | $-3.24M | $-3.92M | $-6.77M | $622.00K | $-2.00K | $-5.50M | $2.86M | $-1.35M | $49.00K |
| Inventory | $- | $- | $- | $- | $12.64M | $-6.79M | $-5.85M | $- | $- | $- | $- | $- | $7.74M | $- | $- | $-673.00K | $353.00K | $- | $- | $- |
| Accounts Payables | $- | $-1.47M | $6.52M | $-14.82M | $-4.05M | $6.79M | $5.85M | $-14.20M | $- | $4.53M | $3.90M | $-11.83M | $1.13M | $12.20M | $-2.67M | $-11.18M | $4.04M | $- | $- | $- |
| Other Working Capital | $19.11M | $20.39M | $4.21M | $-3.85M | $-4.71M | $1.19M | $4.14M | $125.00K | $20.96M | $-5.43M | $4.10M | $2.51M | $7.01M | $5.98M | $-2.35M | $-507.00K | $3.68M | $-166.00K | $-5.95M | $-4.74M |
| Other Non Cash Items | $3.06M | $-21.96M | $50.81M | $56.47M | $13.85M | $57.95M | $1.70M | $1.48M | $1.10M | $685.00K | $570.00K | $425.00K | $-81.00K | $-121.00K | $2.98M | $377.00K | $304.00K | $420.00K | $397.00K | $365.00K |
| Net Cash Provided by Operating Activities | $49.37M | $16.99M | $9.81M | $4.30M | $23.33M | $31.41M | $18.06M | $9.96M | $35.48M | $24.00M | $23.26M | $9.80M | $20.83M | $20.00M | $14.62M | $4.93M | $12.68M | $15.49M | $7.82M | $8.82M |
| Investments in Property Plant and Equipment | $-5.84M | $8.49M | $-6.12M | $-3.58M | $-4.37M | $-4.04M | $-4.18M | $-2.73M | $-3.17M | $-3.32M | $-3.34M | $-2.69M | $-2.42M | $-2.60M | $-2.47M | $-1.41M | $-1.40M | $-1.97M | $-2.23M | $-2.33M |
| Acquisitions Net | $-91.33M | $-6.51M | $- | $-8.65M | $-56.68M | $- | $-7.55M | $- | $-9.43M | $- | $100.00K | $-5.98M | $-246.91M | $- | $-12.07M | $-2.04M | $- | $- | $- | $-675.00K |
| Purchases of Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Sales Maturities of Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Investing Activities | $- | $-7.49M | $-5.69M | $-2.96M | $-3.49M | $-3.73M | $-3.91M | $-2.41M | $- | $-2.93M | $-2.98M | $-2.19M | $-2.27M | $-2.12M | $-2.18M | $-1.19M | $-1.32M | $-1.82M | $-2.05M | $-1.88M |
| Net Cash Used for Investing Activities | $-97.16M | $-5.51M | $-6.12M | $-3.58M | $-61.05M | $-4.04M | $-11.73M | $-2.73M | $-12.60M | $-3.32M | $-3.24M | $-8.68M | $-249.32M | $-2.60M | $-14.54M | $-3.46M | $-1.40M | $-1.97M | $-2.23M | $-3.01M |
| Debt Repayment | $-750.00K | $-750.00K | $6.30M | $-755.00K | $-755.00K | $-755.00K | $-755.00K | $-780.00K | $-830.00K | $-829.00K | $-828.00K | $-826.00K | $-826.00K | $-824.00K | $-1.47M | $-855.00K | $-80.85M | $-40.52M | $-1.79M | $19.03M |
| Common Stock Issued | $- | $-3.71M | $- | $3.71M | $- | $- | $- | $- | $- | $- | $- | $- | $133.35M | $- | $- | $- | $316.30M | $- | $- | $- |
| Common Stock Repurchased | $- | $8.01M | $-7.07M | $-943.00K | $-497.00K | $-170.00K | $-5.67M | $-70.00K | $- | $-515.00K | $-2.26M | $-48.00K | $-172.00K | $- | $- | $- | $- | $-1.02M | $-55.00K | $- |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-1.02M | $- | $- | $- |
| Other Financing Activities | $-553.00K | $-4.86M | $-10.06M | $-9.59M | $-497.00K | $-170.00K | $-5.67M | $-70.00K | $-138.00K | $-515.00K | $-2.70M | $-694.00K | $-2.82M | $-327.00K | $-2.84M | $- | $-3.14M | $- | $-55.00K | $- |
| Net Cash Used Provided by Financing Activities | $-1.30M | $-5.61M | $-3.75M | $-10.35M | $-1.25M | $-925.00K | $-6.42M | $-850.00K | $-968.00K | $-1.34M | $-3.53M | $-1.52M | $-3.64M | $132.20M | $-4.31M | $-855.00K | $232.32M | $-41.29M | $-1.84M | $19.03M |
| Effect of Forex Changes on Cash | $-4.74M | $2.55M | $-117.00K | $-546.00K | $1.61M | $-2.35M | $1.06M | $1.17M | $3.99M | $-3.79M | $-3.30M | $-1.17M | $802.00K | $-1.24M | $103.00K | $-191.00K | $-2.05M | $165.00K | $1.26M | $-251.00K |
| Net Change in Cash | $-53.84M | $8.42M | $-177.00K | $-10.18M | $-37.36M | $24.10M | $972.00K | $7.55M | $25.91M | $15.53M | $13.19M | $-1.56M | $-231.33M | $148.36M | $-4.13M | $430.00K | $241.54M | $-27.60M | $5.00M | $24.59M |
| Cash at End of Period | $179.18M | $233.02M | $224.60M | $224.78M | $234.95M | $272.31M | $248.21M | $247.24M | $239.69M | $213.78M | $198.25M | $185.06M | $186.62M | $417.96M | $269.60M | $273.72M | $273.29M | $31.75M | $59.35M | $54.36M |
| Cash at Beginning of Period | $233.02M | $224.60M | $224.78M | $234.95M | $272.31M | $248.21M | $247.24M | $239.69M | $213.78M | $198.25M | $185.06M | $186.62M | $417.96M | $269.60M | $273.72M | $273.29M | $31.75M | $59.35M | $54.36M | $29.76M |
| Operating Cash Flow | $49.37M | $16.99M | $9.81M | $4.30M | $23.33M | $31.41M | $18.06M | $9.96M | $35.48M | $24.00M | $23.26M | $9.80M | $20.83M | $20.00M | $14.62M | $4.93M | $12.68M | $15.49M | $7.82M | $8.82M |
| Capital Expenditure | $-5.84M | $8.49M | $-6.12M | $-3.58M | $-4.37M | $-4.04M | $-4.18M | $-2.73M | $-3.17M | $-3.32M | $-3.34M | $-2.69M | $-2.42M | $-2.60M | $-2.47M | $-1.41M | $-1.40M | $-1.97M | $-2.23M | $-2.33M |
| Free Cash Flow | $43.53M | $25.47M | $3.69M | $718.00K | $18.96M | $27.37M | $13.88M | $7.23M | $32.31M | $20.67M | $19.92M | $7.11M | $18.41M | $17.40M | $12.15M | $3.52M | $11.28M | $13.52M | $5.59M | $6.49M |
Certara Dividends
Explore Certara's dividend history, including dividend yield, payout ratio, and historical payments.
Certara News
Read the latest news about Certara, including recent articles, headlines, and updates.
Certara Launches Non-Animal Navigator™ Solution to Help Drug Developers Reduce Reliance on Animal Testing
RADNOR, Pa., April 14, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the launch of its Non-Animal Navigator™ solution designed to help biopharmaceutical companies lead the transition ignited by the FDA's Roadmap to Reducing Animal Testing in Preclinical Safety Studies.
Buy Certara After The FDA Announcement
The FDA's phase-out of animal testing for monoclonal antibody therapies boosts Certara's growth prospects, as evidenced by a 15% stock jump. Certara's recently posted a 14.1% revenue increase Y/Y, with significant contributions from biosimulation and Chemaxon businesses. Certara's cautious AI investments align with the FDA's regulatory changes, enhancing its end-to-end biosimulation offerings from drug discovery to clinical trials.
Certara Expands the Simcyp™ Simulator Platform Advancing Biopharmaceutics, Drug-Drug Interaction & Biologic Capabilities
RADNOR, Pa., April 01, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, has released a new version of the Simcyp™ Simulator for physiologically-based pharmacokinetic (PBPK) modeling.
Certara, Inc. (CERT) Q4 2024 Earnings Call Transcript
Certara, Inc. (NASDAQ:CERT ) Q4 2024 Earnings Conference Call February 26, 2025 5:00 PM ET Company Participants David Deuchler - Investor Relations, Gilmartin Group LLC William Feehery - Chief Executive Officer John Gallagher - Chief Financial Officer Conference Call Participants Jeff Garro - Stephens Inc. Michael Cherny - Leerink Partners Christine Rains - William Blair David Windley - Jefferies Constantine Davides - Citizens Securities Andrew Moss - Bank of America Kyle Crews - UBS Operator Good day, and thank you for standing by. Welcome to the Certara Fourth Quarter 2024 Earnings Conference Call.
Certara to Report Fourth Quarter and Full Year 2024 Financial Results on February 26th, 2025 and Participate in Upcoming Investor Conferences
RADNOR, Pa., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it will release financial results for the fourth quarter and full year of 2024 after the market close on Wednesday, February 26th, 2025. Company management will host a conference call to discuss financial results at 5:00PM ET.
Certara to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
RADNOR, Pa., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that Company management will participate in the 43rd Annual J.P. Morgan Healthcare Conference.
Cerrado Gold Provides an Update on its Mont Sorcier High Purity 67%+ Iron Grade Project in Quebec
Detailed Metallurgical test work is ongoing and reaffirms production of DRI grade, 67%+ or better iron concentrate with combined Silica and Alumina below 2.5% Work Programs initiated and DRA Global appointed to deliver NI 43-101 Bankable Feasibility Study by end of Q1 2026 2022 PEA on Mont Sorcier provided an NPV8% of US$1.6 Billion for a 21-year mine life producing 5MT of Iron Concentrate per year (300,000 oz/Au equiv.) generating US$348M per annum in cash flow based upon initial capex of US$574M UKEF and TD Bank have agreed to sponsor 70% of project capital required subject to customary conditions of Export Credit Agency funding (All numbers reported in US dollars) TORONTO, ON / ACCESSWIRE / December 4, 2024 / (TSXV:CERT)(OTCQX:CRDOF) ("Cerrado" or the "Company") is pleased to provide an update on its ongoing work programs to complete a NI 43-101 Bankable Feasibility Study("BFS") by end of Q1 2026 on its High Purity, DRI Grade, +67% iron Mont Sorcier magnetite iron ore project located near Chibougamau, Quebec.
Certara Appoints John Reynders as New Independent Board Member
RADNOR, Pa., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the appointment of John Reynders, PhD, to its Board of Directors, effective October 15, 2024.
Certara to Report Third Quarter 2024 Financial Results on November 6th, 2024
RADNOR, Pa., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it will release financial results for the third quarter of 2024 after the market close on Wednesday, November 6th, 2024. Company management will host a conference call to discuss financial results at 5:00PM ET.
Certara, Inc. (CERT) Q2 2024 Earnings Call Transcript
Certara, Inc. (NASDAQ:CERT ) Q2 2024 Earnings Conference Call August 6, 2024 5:00 PM ET Company Participants David Deuchler - Investor Relations, Gilmartin Group LLC William Feehery - Chief Executive Officer John Gallagher - Chief Financial Officer Conference Call Participants Jeff Garro - Stephens David Windley - Jefferies Dan Clark - Leerink Partners Joe Vruwink - Baird Steve Dechert - KeyBanc Operator Good day and thank you for standing by. Welcome to the Certara Second Quarter 2024 Earnings Conference Call.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for CERT.